论文部分内容阅读
目的:观察金喜素(盐酸拓扑替康TPT蛳9)、顺铂(DDP)联合化疗对老年非小细胞肺癌(NSCLC)的疗效和毒副作用。方法:TPT 0.75 mg·m-2·d-1,第1天~第5天静脉滴注(0.5 h内),DDP 20 mg·m-2·d-1,第1天~第5天静脉滴注,21 d为一周期,按WHO疗效及毒副反应标准评价。结果:25例均化疗2个周期以上,共97个周期,其中完全缓解(CR)1例(4 %),部分缓解(PR)11例(44 %),稳定(SD)10例(40 %),进展(PD)3例(12 %)有效率(RR)48 %,初治者13 例,RR 53.9 %,复治者12例,RR 41.7 %,两组差异无显著性(P>0.05)。主要毒副作用是骨髓抑制,Ⅲ度~ Ⅳ度白细胞减少周期数12.4 %(12/97)。结论:TPT联合DDP治疗非小细胞肺癌有一定客观缓解率,毒副作用轻,耐受性好,值得在临床推广。
OBJECTIVE: To observe the curative effect and toxicity of gold hi-si (topotecan hydrochloride TPT 蛳 9) and cisplatin (DDP) combined chemotherapy on elderly non-small cell lung cancer (NSCLC). Methods: TPT 0.75 mg · m-2 · d-1, intravenous drip (within 0.5 h), DDP 20 mg · m-2 · d-1 on day 1 to day 5, vein from day 1 to day 5 Instillation, 21 d for a cycle, according to the WHO efficacy and toxicity criteria evaluation. Results: All of the 25 patients were treated with more than two cycles of chemotherapy for a total of 97 cycles, of which 1 (4%) had complete remission (CR), 11 (44%) had partial response (PR) ), 3 cases (12%) of patients with progressive (PD) 48% effective rate, 13 newly diagnosed patients with RR of 53.9% and 12 cases of retreatment with RR of 41.7%. There was no significant difference between the two groups ). The main toxic and side effects were myelosuppression. The number of Ⅲ ~ Ⅳ leukopenia cycles was 12.4% (12/97). Conclusion: TPT combined with DDP has a certain objective response rate in non-small cell lung cancer with light toxicity and good tolerability, which is worthy of clinical promotion.